Waste and Abuse Hidden Behind Unnecessarily Large Packaging
Peter Bach, MD, is heading the Evidence Driven Drug Pricing Project, a 3-year initiative that will pilot value- and indication-based payment
structures for drugs, funded by the Laura and John Arnold Foundation.
It's Time to Prove Value and Move the Needle on Quality
Jennie R. Crews, MD, FACP, discusses how her 18 years of diverse activity in the oncology sector would translate into strong leadership for the Association of Community Cancer Centers and its membership of 20,000.
Liquid Biopsy Mania Leaves Questions Unanswered
Many physicians are excited by the possibility of following
the evolving story of their patientsâ€™ cancer no longer
through images including PET scans, but through changes
in the molecular phenotype of their patientsâ€™ tumors.
CMS Pay Cut Proposal Draws Fire
A newly proposed drug reimbursement plan from The Centers for
Medicare & Medicaid has oncology associations up in arms,
whereas a well-known patient advocate and oncologist says he sees
method in the payment scheme.
Caution Advised in Leaping on the Liquid Biopsy Bandwagon
A profusion of so-called â€œliquid
biopsyâ€ tests that extract circulating tumor cells, cell-free DNA, or exosomes from blood and urine are under investigation at
research institutions and startup firms, and in some cases are already being used
to supplement or replace traditional biopsies.
Medicare's Rx for Change: No Spoonful of Sugar
The ongoing value transition got a bit more real in March when The Centers for Medicare
& Medicaid Services introduced a proposal for Medicare Part B drug payment
changes that would even out the margins that physicians make on drug sales.
Are Oral Parity Laws Really Effective?
Oral parity legislation for getting newer drugs to patients under similar
coverage terms as for older drugs often involves a battle that doesnâ€™t stop
when a law is passed.
Payers Still Denying Coverage Despite Clinical Trial Mandate
A mandate enacted after the 2010 Patient Protection and Affordable
Care Act was supposed to improve health coverage for patients
enrolled in clinical trials; however, nearly 63% of cancer centers
and organizations that responded to a recent survey reported
insurance denials of routine care costs associated with patient involvement
in clinical trials during 2014.
Patient Characteristics Hint at Financial Sensitivity to Cancer Care
A study published recently offers help to physicians in recognizing which of their patients would experience heightened sensitivity to the financial strain of cancer care.
Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD
Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma
Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL
Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS
2 Clarke Drive Cranbury, NJ 08512